Skip to main content
OpenTrials
Completed

NCT Number: NCT04165980

Modulatory Effects of Multichannel tDCS During Prolonged Experimental Pain

Corticomotor excitability, pain sensitivity, descending pain control and somatosensory evoked potentials (SEPs) is often altered in acute and chronic pain.

Topical capsaicin generates stable, long-lasting hyperalgesia and ongoing tonic pain in healthy participants, which significantly inhibits corticomotor excitability in the primary motor cortex (M1).

Recent studies (by Fischer et al 2017) indicated that multifocal Transcranial Direct Current Stimulation (tDCS) administered to brain regions linked to the resting state motor network (network-tDCS) could enhance corticomotor excitability in healthy participants compared to single site M1-tDCS.

It remains unknown whether network-tDCS has also the potential to modulate the inhibitory effects on motor cortex excitability, pain sensitivity, descending pain control and SEPs associated with prolonged pain

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Aalborg University

Aalborg, Nordylland, 9000, Denmark

About this study

To date, pain modulation to M1 rs-network tDCS during 8% capsaicin induced pain has not been assessed (Mylius, Borckardt and Lefaucheur, 2012). Further, it is unknown how multichannel tDCS acts on tonic cutaneous pain for approximately 24 hours.

The main objective of these projects are to study and characterize quantitatively the effects of multichannel tDCS in the development of prolonged pain.

It is hypothesized that multichannel tDCS of left M1 resting-state network will reduce the severity of experimentally prolonged pain over the m. first dorsal interosseous (FDI), will increase descending pain control, might possibly increase pain thresholds and simultaneously will modulate the peak-to-peak amplitude of SEPs to electrical painful stimulation. Further, it is hypothesized that descending pain modulation of M1 tDCS will be related to interference with the suppression of cortical excitability

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-Right-handed healthy men and women in the age 21-50 years who speak and understand English

Exclusion criteria

  • Lack of ability to cooperate
  • History of chronic pain or current acute pain
  • Pregnancy
  • Drug addiction defined as the use of cannabis, opioids or other drugs
  • Present and previous neurologic, musculoskeletal or mental illnesses
  • Chili allergies (subproject 1 and 2)
  • Current use of medications that may affect the trial
  • Previous experience with rTMS and tDCS
  • Contraindications to rTMS application (history of epilepsy, metal implants in head or jaw, etc.)
  • Failure to pass the questionnaire for tDCS
  • Failure to pass the "TASS questionnaire" (TASS = Transcranial Magnetic Stimulation Adult Safety Screen) (Rossi et al., 2001)

Treatment and study plan

Transcranial Direct Current Stimulation

Device

Transcranial direct current stimulation delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.

Primary outcomes

  1. Corticomotor excitability

    Time frame: 24 hours

    Corticomotor excitability is expressed as the peak-to-peak amplitude of motor evoked potentials to single-pulse transcranial magnetic stimulation. It is expected that network-tDCS will reduce corticomotor inhibition induced by tonic pain during 24 hours.

Secondary outcomes

  1. Conditioned pain modulation effect

    Time frame: 24 hours

    Conditioned pain modulation effect is an indicator of descending inhibitory control in humans. In this study, it is performed using pressure cuff algometry. The CPM protocol consisted of a constant cuff pressure stimulation (conditioning stimulus) at 70% of the PTT (recorded for pain sensitivity assessment on that day) applied to the left leg and simultaneously one ramped cuff stimulation (test stimulus) at 1 kPa/s applied to the right leg. It is hypothesized that network-tDCS might normalize the CPM effect reduced by tonic pain during 24 hours.

  2. Warm detection thresholds (sensitivity measure)

    Time frame: 24 hours

    Warm detection thresholds will be assessed using a thermode applied on the volar forearm. The thermode will start increasing the temperature from 32 C (Celsius degrees) until the participant can detect a warm sensation and will immediately press a stop button. This task will be repeted a total of 4 times.

    It is hypothesized that 2 daily treatments of active network-tDCS will not modulate this sensitivity measure during prolonged pain due to a small effect size.

  3. Heat pain thresholds (pain sensitivity measure)

    Time frame: 24 hours

    Heat pain thresholds will be assessed using a thermode applied on the volar forearm. The thermode will start increasing the temperature from 32 C (Celsius degrees) until the participant can detect a temperature increment from just "a warm sensation" to an additional of either "burning" or "painful" and will immediately press a stop button. This task will be repeted a total of 3 times.

    It is hypothesized that 2 daily treatments of active network-tDCS will not modulate this pain sensitivity measure during prolonged pain due to a small effect size.

  4. Mechanical pain thresholds (pain sensitivity measure)

    Time frame: 24 hours

    Mechanical pain thresholds (MPT) were assessed using seven pinprick stimulators (MRC Systems GmbH, Germany) exerting forces ranging from 8 mN to 512 mN over the distal part of the volar forearm. Starting with the lightest, each stimulator is applied in an ascending order until the participant reported a perception of sharpness or pain. If the pain threshold is not reached, the value of 1024 mN was registered. The MPT will be expressed as the geometric mean of five series of ascending/descending series of stimuli.

    It is hypothesized that 2 daily treatments of active network-tDCS will not modulate this pain sensitivity measure during prolonged pain due to a small effect size.

  5. Cuff pressure pain sensitivity

    Time frame: 24 hours

    A computer-controlled cuff algometer combined with two 10-cm wide air-pressured cuffs and an electronic visual analogue scale (eVAS; anchored at 0 cm [no pain] and 10 cm [worst pain imaginable]) are used to assess cuff pressure pain detection thresholds (PDT) and pain tolerance thresholds (PTT).

    It is hypothesized that 2 daily treatments of active network-tDCS will not modulate these pain sensitivity measures during prolonged pain due to a small effect size.

  6. Amplitude of SEPs to electrical painful stimulation

    Time frame: 24 hours

    It is expected that the peak to peak amplitude of SEPs (in Cz position) will be modulated by tonic pain during 24 hours and by network-tDCS.

  7. Latency of SEPs to electrical painful stimulation

    Time frame: 24 hours

    it is expected that the latency of SEPs will remain unchanged during the 24 hours period and will not be affected by neither prolonged pain nor by network-tDCS.

Sponsors and collaborators

Lead sponsor

Aalborg University

Other

Registry information

Official study title

Effects of Non-invasive Brain Stimulation Methods in Experimentally Induced Pain

Important dates

Study start
2019
Primary completion
2019
Study completion
2020
First posted
Nov 18, 2019
Registry last updated
Jun 24, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.